ASP Isotopes (ASPI) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
16 Nov, 2026Executive summary
Q3 revenue rose to $5.1M from $1.3M YoY, while operating loss widened to $40.5M from $15.0M; 9M revenue was $14.4M and operating loss $99.6M.
Results include newly consolidated Renergen, Numed and ECNP; enriched-isotope sales had not begun by September 30, 2026.
Liquidity was $201.7M in cash and cash equivalents; management expects available resources to cover operating and capital needs for more than 12 months from issuance.
Financial highlights
Q3 revenue was $5.124M, up from $1.271M YoY; product revenue was $5.124M and collaboration revenue was nil.
9M revenue was $14.427M, up from $3.571M YoY, including $13.627M product revenue and $0.800M TerraPower collaboration revenue.
Q3 gross profit was $0.793M vs. $0.242M; operating loss was $40.515M vs. $14.987M. 9M gross profit was $3.940M vs. $1.141M; operating loss was $99.598M vs. $34.908M.
Net loss attributable to shareholders was $30.371M in Q3 and $70.833M for 9M; attributable loss per share was $0.21 and $0.55, respectively.
Q3 other income included an $11.250M convertible-note extinguishment gain; 9M other income was $9.022M, versus $61.817M of other expense in 2025.
Outlook and guidance
Initial Si-28 shipments are targeted for Q4 2026; initial C-14 shipments may occur in 2027, dependent on customer feedstock timing and quality; Yb-176 shipments are targeted for 2027.
Management expects Helium and LNG margins to improve in 2027 as production volumes rise and fixed costs are absorbed over a larger production base.
Phase 2 of the Virginia Gas Project is estimated to cost more than $1.0B; a conditional DFC commitment of up to $500M was extended to July 1, 2029, while definitive financing remains unexecuted.
Management expects R&D and SG&A to increase substantially as isotope development, commercialization and public-company requirements expand.
The ENDRA merger is anticipated in Q4 2026 or, subject to an extension, Q1 2027; closing depends on shareholder approval, financing and other conditions.
Latest events from ASP Isotopes
- Scaling isotope production and radiopharmacies toward a $300m EBITDA target by 2031.ASPI
Emerging Growth Conference 97 - Proprietary enrichment tech, global expansion, and strong financials drive $300–$700M 2031 EBITDA target.ASPI
CMD 2026 - Commercial production of isotopes and helium begins, targeting global supply gaps and strong growth.ASPI
Emerging Growth Conference - Quarterly revenue grew to $5.1M, net loss narrowed, and Renergen acquisition expanded operations.ASPI
Q2 2026 - Vertically integrated isotope and helium producer targets global expansion and strong financial growth.ASPI
Canaccord Genuity's 46th Annual Growth Conference - Phase I helium shipments begin September, with major expansion and strong contracts driving growth.ASPI
Investor update - Advancing isotope enrichment for semiconductors, medicine, and energy with 2026 milestones.ASPI
Corporate presentation - Expanding isotope enrichment and supply to critical markets with strong growth targets.ASPI
Corporate presentation - Commercial production ramped up across three plants, with strong cash reserves and growth outlook.ASPI
Q4 2024